Our objective was to assess, using clinical trial simulation, the feasibility of a fixed 200-µg dose of darbepoetin alfa (Aranesp) administered every 2 weeks in chemotherapy-induced anemia. A pharmacokinetic/pharmacodynamic
Bin Yao, MS
Advertisement
Articles by Bin Yao, MS
Advertisement
Latest Updated Articles
- Clinical Trial Simulation of a 200-µg Fixed Dose of Darbepoetin Alfa in Chemotherapy-Induced Anemia
Published: October 1st 2002 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears Phase 3 Lacutamab Protocol in Cutaneous T-Cell Lymphomas
2
Identifying and Pursuing Optimization of ADC Treatment in Cancer
3
Finding a “Sweet Spot” for Smoldering Multiple Myeloma Management
4
How Supportive Care Methods Can Improve Oncology Outcomes
5
